Dihydronaphthalene derivative
US-2017327439-A1 · Nov 16, 2017 · US
Compounds having S1P5 receptor agonistic activity
US11198672B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11198672-B2 |
| Application number | US-201916970865-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 21, 2019 |
| Priority date | Feb 22, 2018 |
| Publication date | Dec 14, 2021 |
| Grant date | Dec 14, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A compound represented by the general formula (V)wherein all the symbols are as defined in the specification, has an improved balance of the agonist activity against the S1P5 receptor relative to the S1P1 receptor, and can thus serve as a therapeutic agent for S1P5-mediated diseases such as schizophrenia and Binswanger's disease and other neurodegenerative diseases.
First claim
Opening claim text (preview).
The invention claimed is: 1. A compound or a pharmaceutically acceptable salt thereof, wherein the compound is 1-[[(3S)-3-methyl-6-(4,4,4-trifluorobutoxy)-3,4-dihydronaphthalen-2-yl]methyl]azetidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof. 2. A compound of the following structure: 3. A pharmaceutically acceptable salt of the compound of the following structure:
Assignees
Inventors
Classifications
containing six-membered aromatic rings and other rings · CPC title
- C07D205/04Primary
having no double bonds between ring members or between ring members and non-ring members · CPC title
Drugs for immunological or allergic disorders · CPC title
Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals · CPC title
- C07D403/04Primary
directly linked by a ring-member-to-ring-member bond · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11198672B2 cover?
- A compound represented by the general formula (V)wherein all the symbols are as defined in the specification, has an improved balance of the agonist activity against the S1P5 receptor relative to the S1P1 receptor, and can thus serve as a therapeutic agent for S1P5-mediated diseases such as schizophrenia and Binswanger's disease and other neurodegenerative diseases.
- Who is the assignee on this patent?
- Ono Pharmaceutical Co
- What technology area does this patent fall under?
- Primary CPC classification C07D205/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Dec 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).